Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Condition: Multiple Myeloma Intervention: Drug: Elranatamab Sponsors: Odense University Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
Conditions: Seborrheic Dermatitis; Papulopustular Rosacea Interventions: Drug: PF-07038124; Drug: Placebo Ointment Sponsors: Icahn School of Medicine at Mount Sinai; Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
